Clinical Trial

A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and effectiveness of luspatercept in participants who require regular blood cell transfusions due to b-thalassemia and myelodysplastic syndromes in India
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2023-05-26; most recent amendment 2025-10-15.
Status change: Recruiting → Active, Not Recruiting 2025-04-15
Status change: Not Yet Recruiting → Recruiting 2023-09-19
Trial Details
NCT Number NCT05891249
Lead Sponsor Bristol-Myers Squibb
Conditions Anemia
Enrollment 85 participants
Start Date 2023-06-05
Primary Completion 2028-12-16 (estimated)
Study Completion 2028-12-16 (estimated)
Updated on ClinicalTrials.gov 2025-10-20